论文部分内容阅读
近年已明确,淋巴细胞在白细胞介素-Ⅱ(IL-2)存在下培养能诱导获得对自体癌细胞显示杀伤作用的淋巴因子活化杀伤细胞(LAK细胞),并报道过应用自体LAK细胞作过继性免疫治疗(AIT)对各种癌患者的有效性。今作者对原发性肝细胞癌息者施行了自体LAK细胞加IL-2经肝动脉给予的AIT,研究了其临床疗效。以6例原发性肝细胞癌(PHCC)息者为对象,施行了经肝动脉的AIT法。LAK细胞每周2次经肝动脉给予;同时安置自动注射泵,通过经股深动脉放置于固有动脉中的自动注射导管将IL-2(1000～2000u/天)注入。以LAK及NK活性作为淋巴细胞活性参数,又以Daudi细胞、K-562细胞分别作为LAK、NK细胞的靶细
In recent years, it has been clarified that lymphocytes cultured in the presence of interleukin-II (IL-2) can induce lymphokine activated killer cells (LAK cells) that show killing effect on autologous cancer cells, and use of autologous LAK cells has been reported as adoptive The effectiveness of sexual immunotherapy (AIT) in various cancer patients. The present authors performed AIT on autologous LAK cells plus IL-2 via hepatic artery in patients with primary hepatocellular carcinoma, and studied its clinical efficacy. For 6 patients with primary hepatocellular carcinoma (PHCC), the transarterial AIT method was performed. LAK cells were given twice a week via the hepatic artery; an automatic syringe pump was also placed and IL-2 (1000 to 2000 u/day) was injected through an autoinjection catheter placed in the proper artery through the deep femoral artery. LAK and NK activity were used as lymphocyte activity parameters, and Daudi cells and K-562 cells were used as targets for LAK and NK cells, respectively.